Literature DB >> 9151799

Inhibition of human colon cancer cell growth by selective inhibition of cyclooxygenase-2.

H Sheng1, J Shao, S C Kirkland, P Isakson, R J Coffey, J Morrow, R D Beauchamp, R N DuBois.   

Abstract

A considerable amount of evidence collected from several different experimental systems indicates that cyclooxygenase-2 (COX-2) may play a role in colorectal tumorigenesis. Large epidemiologic studies have shown a 40-50% reduction in mortality from colorectal cancer in persons taking aspirin or other nonsteroidal antiinflammatory drugs on a regular basis. One property shared by all of these drugs is their ability to inhibit COX, a key enzyme in the conversion of arachidonic acid to prostaglandins. Two isoforms of COX have been characterized, COX-1 and COX-2. COX-2 is expressed at high levels in intestinal tumors in humans and rodents. In this study, we selected two transformed human colon cancer cell lines for studies on the role of COX-2 in intestinal tumorigenesis. We evaluated HCA-7 cells which express high levels of COX-2 protein constitutively and HCT-116 cells which lack COX-2 protein. Treatment of nude mice implanted with HCA-7 cells with a selective COX-2 inhibitor (SC-58125), reduced tumor formation by 85-90%. SC-58125 also inhibited colony formation of cultured HCA-7 cells. Conversely, SC-58125 had no effect on HCT-116 implants in nude mice or colony formation in culture. Here we provide evidence that there may be a direct link between inhibition of intestinal cancer growth and selective inhibition of the COX-2 pathway.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9151799      PMCID: PMC508057          DOI: 10.1172/JCI119400

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  44 in total

1.  Epidermal growth factor receptor activation induces nuclear targeting of cyclooxygenase-2, basolateral release of prostaglandins, and mitogenesis in polarizing colon cancer cells.

Authors:  R J Coffey; C J Hawkey; L Damstrup; R Graves-Deal; V C Daniel; P J Dempsey; R Chinery; S C Kirkland; R N DuBois; T L Jetton; J D Morrow
Journal:  Proc Natl Acad Sci U S A       Date:  1997-01-21       Impact factor: 11.205

2.  Human chromosome 3 corrects mismatch repair deficiency and microsatellite instability and reduces N-methyl-N'-nitro-N-nitrosoguanidine tolerance in colon tumor cells with homozygous hMLH1 mutation.

Authors:  M Koi; A Umar; D P Chauhan; S P Cherian; J M Carethers; T A Kunkel; C R Boland
Journal:  Cancer Res       Date:  1994-08-15       Impact factor: 12.701

3.  Aspirin use and the risk for colorectal cancer and adenoma in male health professionals.

Authors:  E Giovannucci; E B Rimm; M J Stampfer; G A Colditz; A Ascherio; W C Willett
Journal:  Ann Intern Med       Date:  1994-08-15       Impact factor: 25.391

4.  Differential inhibition of human prostaglandin endoperoxide H synthases-1 and -2 by nonsteroidal anti-inflammatory drugs.

Authors:  O Laneuville; D K Breuer; D L Dewitt; T Hla; C D Funk; W L Smith
Journal:  J Pharmacol Exp Ther       Date:  1994-11       Impact factor: 4.030

5.  Selective inhibition of inducible cyclooxygenase 2 in vivo is antiinflammatory and nonulcerogenic.

Authors:  J L Masferrer; B S Zweifel; P T Manning; S D Hauser; K M Leahy; W G Smith; P C Isakson; K Seibert
Journal:  Proc Natl Acad Sci U S A       Date:  1994-04-12       Impact factor: 11.205

6.  Up-regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas.

Authors:  C E Eberhart; R J Coffey; A Radhika; F M Giardiello; S Ferrenbach; R N DuBois
Journal:  Gastroenterology       Date:  1994-10       Impact factor: 22.682

7.  Involvement of protein kinase C and an elastase-like enzyme in the processing of transforming growth factor-alpha in human colon carcinoma cell lines.

Authors:  A E Levine
Journal:  Int J Cancer       Date:  1994-07-01       Impact factor: 7.396

8.  Expression and selective inhibition of the constitutive and inducible forms of human cyclo-oxygenase.

Authors:  J K Gierse; S D Hauser; D P Creely; C Koboldt; S H Rangwala; P C Isakson; K Seibert
Journal:  Biochem J       Date:  1995-01-15       Impact factor: 3.857

9.  Regulation of eicosanoid production and mitogenesis in rat intestinal epithelial cells by transforming growth factor-alpha and phorbol ester.

Authors:  R N DuBois; J Awad; J Morrow; L J Roberts; P R Bishop
Journal:  J Clin Invest       Date:  1994-02       Impact factor: 14.808

10.  Isolation of biologically active ribonucleic acid from sources enriched in ribonuclease.

Authors:  J M Chirgwin; A E Przybyla; R J MacDonald; W J Rutter
Journal:  Biochemistry       Date:  1979-11-27       Impact factor: 3.162

View more
  134 in total

1.  COX-1 and COX-2 products in the gut: therapeutic impact of COX-2 inhibitors.

Authors:  B J Whittle
Journal:  Gut       Date:  2000-09       Impact factor: 23.059

Review 2.  Aspirin and other anti-inflammatory drugs.

Authors:  S J Vane
Journal:  Thorax       Date:  2000-10       Impact factor: 9.139

3.  The anti-apoptotic effect of leukotriene D4 involves the prevention of caspase 8 activation and Bid cleavage.

Authors:  Katarina Wikström; Maria Juhas; Anita Sjölander
Journal:  Biochem J       Date:  2003-04-01       Impact factor: 3.857

4.  Sulindac sulfide, but not sulindac sulfone, inhibits colorectal cancer growth.

Authors:  C S Williams; A P Goldman; H Sheng; J D Morrow; R N DuBois
Journal:  Neoplasia       Date:  1999-06       Impact factor: 5.715

Review 5.  Role of cyclooxygenase-2 in the angiogenesis of colorectal cancer.

Authors:  Milind Rao; Wenxuan Yang; Alexander M Seifalian; Marc C Winslet
Journal:  Int J Colorectal Dis       Date:  2003-06-03       Impact factor: 2.571

6.  Selective visualization of cyclooxygenase-2 in inflammation and cancer by targeted fluorescent imaging agents.

Authors:  Md Jashim Uddin; Brenda C Crews; Anna L Blobaum; Philip J Kingsley; D Lee Gorden; J Oliver McIntyre; Lynn M Matrisian; Kotha Subbaramaiah; Andrew J Dannenberg; David W Piston; Lawrence J Marnett
Journal:  Cancer Res       Date:  2010-05-01       Impact factor: 12.701

7.  15-Hydroxyprostaglandin dehydrogenase, a COX-2 oncogene antagonist, is a TGF-beta-induced suppressor of human gastrointestinal cancers.

Authors:  Min Yan; Ronald M Rerko; Petra Platzer; Dawn Dawson; Joseph Willis; Min Tong; Earl Lawrence; James Lutterbaugh; Shilong Lu; James K V Willson; Guangbin Luo; Jack Hensold; Hsin-Hsiung Tai; Keith Wilson; Sanford D Markowitz
Journal:  Proc Natl Acad Sci U S A       Date:  2004-12-01       Impact factor: 11.205

8.  Phosphatidylinositol 3-kinase mediates proliferative signals in intestinal epithelial cells.

Authors:  H Sheng; J Shao; C M Townsend; B M Evers
Journal:  Gut       Date:  2003-10       Impact factor: 23.059

9.  ESE-1/EGR-1 pathway plays a role in tolfenamic acid-induced apoptosis in colorectal cancer cells.

Authors:  Seong-Ho Lee; Jae Hoon Bahn; Chang Kyoung Choi; Nichelle C Whitlock; Anthony E English; Stephen Safe; Seung Joon Baek
Journal:  Mol Cancer Ther       Date:  2008-12       Impact factor: 6.261

10.  Inhibition of COX-2 with NS-398 decreases colon cancer cell motility through blocking epidermal growth factor receptor transactivation: possibilities for combination therapy.

Authors:  N Banu; A Buda; S Chell; D Elder; M Moorghen; C Paraskeva; D Qualtrough; M Pignatelli
Journal:  Cell Prolif       Date:  2007-10       Impact factor: 6.831

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.